|
|||||
|
|
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine
SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The company's participation coincides with the recent FDA approval of its Micro Typing Systems (MTS) DAT Card and the continued expansion of its comprehensive direct antiglobulin testing and immunohematology portfolio.
The MTS DAT Card completes QuidelOrtho's gel-based solution for direct antiglobulin testing. When paired with the ORTHO VISION™ Platform, it combines proven column agglutination technology with advanced software capabilities – including reflex testing and as-needed quality control – to help laboratories deliver faster, more reliable results for patients who depend on timely transfusion decisions.
"The AABB Annual Meeting brings together the world's foremost leaders in blood and biotherapies," said Michelle Mullens, Global Product Manager, Portfolio Solutions Transfusion Medicine, at QuidelOrtho. "Our participation reinforces our dedication to driving innovation that advances laboratory performance and enhances efficiency, helping to improve patient outcomes worldwide."
Featured education sessions
Poster presentations
These posters offer insights into performance and reliability metrics that support confident decision-making in the lab.
Product demonstrations
Learn more and register
Explore the full agenda and secure your spot: https://cvent.me/bA4rgD?utm_source=webmax&utm_campaign=aabb25&utm_medium=media&utm_term=register-now&RefId=media
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
|
Investor Contact: Juliet Cunningham Vice President, Investor Relations |
Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications |
SOURCE QuidelOrtho Corporation

| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-05 | |
| Nov-05 | |
| Nov-05 | |
| Nov-03 | |
| Nov-03 | |
| Oct-30 | |
| Oct-29 | |
| Oct-23 | |
| Oct-23 | |
| Oct-22 | |
| Oct-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite